Should You Still Hold GMED Stock in Your Portfolio?
Globus Medical is growing musculoskeletal market share with new product launches, strong finances and international expansion plans.
Zacks·6h ago
More News
Axecap Investments LLC Has $4.89 Million Position in Phibro Animal Health Corporation $PAHC
Axecap Investments LLC cut its holdings in Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) by 32.6% during the 3rd quarter, according to its most recent 13F filing with the Securities...
MarketBeat·1d ago
Here's Why You Should Hold DexCom Stock in Your Portfolio for Now
DXCM looks poised for growth as CGM demand expands, G7 and One+ adoption accelerates, and strong Q4 results support a hold stance.
Zacks·4d ago
Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 2,932 Shares
Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) CEO Jack Bendheim sold 2,932 shares of Phibro Animal Health stock in a transaction dated Thursday, January 15th. The stock was sold at...
MarketBeat·5d ago
Insider Selling: Phibro Animal Health (NASDAQ:PAHC) CEO Sells 3,651 Shares of Stock
Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) CEO Jack Bendheim sold 3,651 shares of the business's stock in a transaction on Wednesday, January 14th. The shares were sold at an...
MarketBeat·5d ago
Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 7,551 Shares
Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) CEO Jack Bendheim sold 7,551 shares of the company's stock in a transaction dated Tuesday, January 13th. The stock was sold at an...
MarketBeat·5d ago
CLOV Reports MA Membership Growth, Signals GAAP Profitability in 2026
Clover Health posts 53% AEP PPO membership growth, lifts total members to 153,000, and says the momentum positions it for GAAP net income profitability in 2026.
Zacks·5d ago
Phibro Animal Health Stock Climbs 90.9% in a Year: What's Driving It?
PAHC shares are up 90.9% this year, fueled by surging vaccine sales, new Brazil capacity and rapid growth across emerging markets.
Zacks·5d ago
Is it Apt to Retain HAE Stock in Your Portfolio for Now?
Haemonetics' plasma and hemostasis franchises show solid growth potential, but macro headwinds and competition cloud the near-term outlook.
Zacks·5d ago
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
FMS' acquisitions, partnerships and global reach fuel growth, even as rising costs and optimization efforts weigh on near-term performance.